Avenue Therapeutics Inc. (NASDAQ:ATXI) shares traded 63.11% higher at $1.99 on Wall Street last session.
In accordance with the data, 1 analysts cover Avenue Therapeutics Inc. (NASDAQ:ATXI). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $180.00 and a low of $180.00, we find $180.00. Given the previous closing price of $1.22, this indicates a potential upside of 14654.1 percent. ATXI stock price is now 38.39% away from the 50-day moving average and -48.28% away from the 200-day moving average. The market capitalization of the company currently stands at $9.13M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 1 analysts and a buy by 0. Brokers who have rated the stock have averaged $180.00 as their price target over the next twelve months.
.
In other news, InvaGen Pharmaceuticals, Inc., 10% Owner sold 388,888 shares of the company’s stock on Oct 11. The stock was sold for $2,999,882 at an average price of $7.71. Upon completion of the transaction, the 10% Owner now directly owns 0 shares in the company, valued at $0.0. Insiders disposed of 388,888 shares of company stock worth roughly $0.77 million over the past 1 year. A total of 18.45% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ATXI stock. A new stake in Avenue Therapeutics Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $71,000. TWO SIGMA INVESTMENTS, LP invested $29,000 in shares of ATXI during the first quarter. In the first quarter, MORGAN STANLEY acquired a new stake in Avenue Therapeutics Inc. valued at approximately $3,000. In total, there are 21 active investors with 1.60% ownership of the company’s stock.
Avenue Therapeutics Inc. (NASDAQ: ATXI) opened at $1.2500 on Tuesday. During the past 12 months, Avenue Therapeutics Inc. has had a low of $1.06 and a high of $18.75. The fifty day moving average price for ATXI is $1.4380 and a two-hundred day moving average price translates $3.8476 for the stock.
The latest earnings results from Avenue Therapeutics Inc. (NASDAQ: ATXI) was released for Jun, 2022.
Avenue Therapeutics Inc.(ATXI) Company Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
